BioSpace News Archive

Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced that Proteostasis management will present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 20, 2020

Collaboration with WuXi Diagnostics and Mayo Clinic on serology test will complement Thermo Fisher’s widely adopted TaqPath COVID-19 molecular diagnostic test [13-May-2020] WALTHAM, Mass. , May 13, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced it will expand its response to the COVID-19 pandemic by devel

MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the first quarter ended March 31, 2020 at 7:00 am Eastern Time on Wednesday, May 20, 2020. Following the release, MediWound’s management will host a conference call and live webcast on Wednesday, May 20, 2020 a

BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent, U.S. 10,596,169, for methods of treating severe chemotherapy-induced neutropenia (CIN) from Taxane in cancer patients by administering its lead asset Plinabulin, wit

-- Revised URIROX-2 Trial Design to Potentially Reduce Size and Cost of Trial -- -- Finalized Protocol and Selected Contract Research Organization for Phase 1 Clinical Trial of ALLN-346 -- -- Presenting Late-Breaking Abstract on Kidney Stone Risk and Association with Urinary Oxalate Levels in Conjunction with AUA Virtual Experience -- NEWTON, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to devel

• First presentation of a novel approach to potentially cure HIV - An in vivo study demonstrated a 164 percent increase in engraftment of genetically modified cells Poster Presentation - http://www.enochianbio.com/wp-content/uploads/2020/05/Final-Poster-SyngeneicMouse_431_ASGCT_Poster_Final-05112020-2.pdf Slide Presentation - http://www.enochianbio.com/wp-content/uploads/2020/05/Final-Presentation-SyngeneicMouse_431_ASGCT_Final-05112020.pdf - A second study provides

AbbVie Inc. (NYSE:ABBV) (“AbbVie”) announced today the final results of the offers to exchange (each, an “Exchange Offer” and, collectively, the “Exchange Offers”) any and all outstanding notes of certain series issued by Allergan Finance, LLC (“Allergan Finance”), Allergan, Inc. (“Allergan Inc”), Allergan Sales, LLC (“Allergan Sal

Happiness Biotech Group Limited (the “Company” or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today that the Company has successfully developed an innovative cultivation technology of lucidum, which enables the Company to reduce the cost of growing lucidum - one of the main raw materials of the Company’s products, by over 30%.

Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that it will participate in the upcoming 2020 RBC Capital Markets Global Healthcare Conference.

Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the results of a pre-clinical study of LPCN 1144.